E2F1 and neoplasm: In MCF-7 cell lines, combination therapy enhanced the downregulation of essential components of the cell cycle (HMMR, AURKB, BIRC5) that control proliferative activities and tumour growth alongside downregulation of the anti-senescence markers FOXM1 and E2F1 [30].